Focused on bringing value to cancer care by developing quality orally delivered oncology products

Optimized treatments to innovate care for patients

Prioritizing the development of an enhanced treatment for metastatic castration-resistant prostate cancer (mCRPC)

Our first investigational drug candidate in development utilizes SoluMatrix Fine Particle Technology™ to create a differentiated treatment option for patients living with mCRPC

Prostate cancer is the most common cancer in men1 and can pose challenges across the spectrum of treatment, from the efficacy and individualization of care to cost.2

We are dedicated to making a meaningful impact in the lives of men living with mCRPC and those who care for them. Utilizing the fine-particle manufacturing process of SoluMatrix® technology, we can deliver new oral therapeutic solutions that may help address and serve the needs of patients.3

We have completed Phase I studies evaluating the bioequivalence, food effect and drug interactions of our lead compound in healthy subjects. Our soon-to-be released pivotal study focuses on the pharmacodynamics endpoints of serum testosterone and PSA levels, as well as safety and pharmacokinetics in mCRPC patients. (NCT02737332)

Churchill Pipeline

Our emerging pipeline will include the development of additional oral cancer treatments created with SoluMatrix Fine Particle Technology™

We aim to further expand our pipeline through strategic partnership opportunities that apply our SoluMatrix® technology to other trusted orally delivered cancer medicines currently limited by solubility challenges

1 American Cancer Society: Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society, 2017
2 Roehrborn CG (2011). The economic burden of prostate cancer. BJU International, 108(6):806-13.
3 Churchill Pharmaceuticals Data on File.